EXOR N.V.
DELISTING OF EXOR’S ORDINARY SHARES FROM EURONEXT MILAN
EXOR N.V.
EXOR N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM
EXOR N.V.
EXOR N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM
EXOR N.V.
DELISTING OF EXOR’S ORDINARY SHARES FROM EURONEXT MILAN WITH EFFECT FROM 27 SEPTEMBER 2022
EXOR N.V.
EXOR N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM
EXOR N.V.
EXOR’S BOARD OF DIRECTORS APPROVES HALF-YEAR 2022 RESULTS
EXOR N.V.
EXOR N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM
EXOR N.V.
EXOR N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM
EXOR N.V.
EXOR N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM
EXOR N.V.
EXOR N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM
EXOR N.V.
DELISTING OF EXOR’S ORDINARY SHARES FROM EURONEXT MILAN WITH EFFECT FROM 27 SEPTEMBER 2022
EXOR N.V.
ADMISSION TO LISTING AND TRADING ON EURONEXT AMSTERDAM REQUEST OF DELISTING FROM EURONEXT MILAN
EXOR N.V.
EXOR N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM
EXOR N.V.
APPROVAL BY AFM OF LISTING PROSPECTUS
EXOR N.V.
APPROVAL BY EURONEXT OF ADMISSION TO LISTING AND TRADING
EXOR N.V.
EXOR TO TRANSITION ITS STOCK EXCHANGE LISTING TO EURONEXT AMSTERDAM TO ALIGN WITH THE COMPANY’S DUTCH LEGAL STRUCTURE
EXOR N.V.
AGREEMENT TO ACQUIRE 10% OF INSTITUT MÉRIEUX CLOSED
EXOR N.V.
EXOR COMPLETES THE SALE OF PARTNERRE TO COVÉA FOR A TOTAL CASH CONSIDERATION OF $9.3 BILLION (€8.6 BILLION)
EXOR N.V.
Institut Mérieux and Exor announce a long-term partnership in global healthcare
EXOR N.V.
ACQUISITION OF 45% OF LIFENET HEALTHCARE CLOSED
EXOR N.V.
EXOR N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM
EXOR N.V.
EXOR N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM
EXOR N.V.
EXOR N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM
EXOR N.V.
EXOR APPOINTS AJAY BANGA AS CHAIRMAN